BioStem Technologies to acquire wound care products and technologies from ProgenaCare Global
213.8MUSD
Type
Common Stock
Exchange
OTCQB
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US0906842002
CUSIP
-
Sector
Healthcare
Industry
Biotechnology
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
-
PEG Ratio
-
Book Value
-0.08
Dividend Share
-
Dividend Yield
-
Earnings Share
-0.73
Wall Street Target Price
32.5
EPS Estimate Current Year
1.41
EPS Estimate Next Year
2.29
EPS Estimate Current Quarter
0.47
EPS Estimate Next Quarter
0.65
Most Recent Quarter
-
Revenue TTM
131,437,112
Gross Profit TTM
5,993,448
EBITDA
12,974,078
Profit Margin
0.00%
Return On Assets TTM
17.01%
Return On Equity TTM
126.37%
Revenue Per Share TTM
1.217
Qtly Revenue Growth YOY
6872.30%
Diluted Eps TTM
-0.73
Qtly Earnings Growth YOY
0.00%
Trailing PE
0.00
Forward PE
5
Price Sales TTM
28.7823
Price Book MRQ
0
Enterprise Value Revenue
36
Enterprise Value EBITDA
-24
170.75
3.58%122.50
2.25%281.51
1.65%687.05
0.35%444.31
0.10%625.30
0.00%190.00
0.00%85.16
-0.61%98.25
-0.46%648.10
-0.14%BioStem Technologies to acquire wound care products and technologies from ProgenaCare Global